Dan Jin, Tianfei Lu, Ming Ni, Han Wang, Jiang Zhang, Chenpeng Zhong, Chuan Shen, Jun Hao, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski, Jianjun Zhang, Ning Xu, Yuan Zhai – 13 February 2020 – Farnesoid X receptor (FXR) is the nuclear receptor of bile acids and is involved in innate immune regulation. FXR agonists have been shown to protect multiple organs from inflammatory tissue injuries. Because liver expresses high levels of FXR, we explored the potential therapeutic benefits and underlying mechanisms of pharmacologic FXR activation in a murine model of partial liver warm ischemia.

12 February 2020

Jean‐Charles Nault, Augusto Villanueva – 11 February 2020 – The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune‐based therapies and biomarker‐driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients.

Lai Wei, Pik Eu Jason Chang, Quentin M. Anstee – 11 February 2020

Shuya Zhang, Huan Liu, Meimei Yin, Xiuying Pei, Angelika Hausser, Eri Ishikawa, Sho Yamasaki, Zheng Gen Jin – 11 February 2020

James M. Paik, Pegah Golabi, Youssef Younossi, Alita Mishra, Zobair M. Younossi – 11 February 2020

Samer Gawrieh, David E. Kleiner, Naga Chalasani, Scott Vanderbeck – 11 February 2020

10 February 2020

10 February 2020

Alyson Kaplan, Russell Rosenblatt, Nicholas W. Russo, Robert S. Brown, Joseph F. Pisa, Petra Hirsova, Robert E. Schwartz, Enis Kostallari, Nidhi Jalan‐Sakrikar, Rajab Idriss, Hirsh Trivedi, Daryl T.Y. Lau, Amaia Navarro‐Corcuera – 10 February 2020